HAIFA, Israel, Sept. 1 /PRNewswire/ -- Elscint Ltd. (NYSE: ELT), a
subsidiary of Elbit Medical Imaging Ltd. (Nasdaq: EMITF), announced today that
in light of strategic discussions regarding Elscint's future, the Board of
Directors of the Company has appointed Mr. Emmanuel Gill as Chief Executive
Officer of Elscint Ltd., in addition to his capacity as Chairman of the Board
of Directors of the Company.
Mr. Jonathan Adereth, President and Chief Executive Officer of Elscint,
has concluded his duties as President and CEO. Mr. Adereth will remain on the
Board of Directors of the Company.
The Board of Directors expressed its gratitude and appreciation to Mr.
Adereth for his important role in the development and advancement of Elscint
during a period of 30 years, in which he served in various R&D and marketing
positions, and as the President & CEO of the Company.
Elscint is an advanced medical imaging company serving healthcare
professionals worldwide. Guided by the philosophy of applying unique
technologies for the advancement of cost-effective healthcare, Elscint
designs, manufactures, sells and services a wide range of sophisticated
computer-based medical imaging products including Computerized Tomography
(CT), Magnetic Resonance Imaging (MRI), Nuclear Medicine (NM) and Mammography
systems.
SOURCE Elscint Ltd.
 back to top
Related links:
http://www.elscint.co.il
CONTACT:
Emmanuel Gill, Chairman of the Board of
Elscint, 972-4-855-0219; General Info, Laurie Berman,
310-442-0599, or Media Info, Alicia Nieva-Woodgate, 415-986-1591,
or Investor Info, Brian Gill, 212-661-8030, all of The Financial
Relations Board
NOTE TO EDITORS: For further information on Elscint, via
facsimile at no cost, please call 1-800-PRO-INFO and enter
company code 206 or ticker symbol ELT.
|
